Holen Sie sich die Stockscreener-App
26.29
1.35%
0.395
Schlusskurs vom Vortag:
$25.89
Offen:
$25.89
24-Stunden-Volumen:
36,138
Relative Volume:
0.16
Marktkapitalisierung:
$733.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-4.696
EPS:
-5.5973
Netto-Cashflow:
$-73.92M
1W Leistung:
-7.98%
1M Leistung:
+34.56%
6M Leistung:
-19.34%
1J Leistung:
+59.71%
1-Tages-Spanne:
$25.41
$26.77
1-Wochen-Bereich:
$25.41
$30.48
52-Wochen-Spanne:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Vergleichen Sie LENZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
26.26 | 733.51M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.19 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.09 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
622.36 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.69 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.42 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
Market Recap Check: LENZ Therapeutics Inc (LENZ)’s Negative Finish at 25.89, Up/Down -11.03 - DWinneX
LENZ Therapeutics Announces Participation in BofA Securities 2025 Health Care Conference - Nasdaq
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference - The Manila Times
First-Ever Presbyopia Eye Drop Treatment: LENZ Therapeutics Reveals Latest Progress at BofA Conference - Stock Titan
Barclays PLC Increases Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
JPMorgan Chase & Co. Purchases 2,643 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Renaissance Technologies LLC Sells 23,900 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Legal & General Group Plc Has $252,000 Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics to Host Webcast on First Quarter 2025 Financial Results and Corporate Developments - Nasdaq
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025 - The Manila Times
Revolutionary Presbyopia Treatment Developer LENZ Therapeutics Announces Q1 2025 Earnings Date - Stock Titan
Presbyopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight - The Globe and Mail
ProfittoPath - TradingView
LENZ Therapeutics Inc (LENZ)’s stock chart: A technical perspective - uspostnews.com
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Geode Capital Management LLC - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Alliancebernstein L.P. - Defense World
LENZ Therapeutics’ (LENZ) Buy Rating Reiterated at HC Wainwright - Defense World
Before Buying LENZ Therapeutics Inc (NASDAQ: LENZ) Stock, Read This First - Stocksregister
LENZ Therapeutics (NASDAQ:LENZ) Now Covered by Analysts at Piper Sandler - Defense World
Form 424B3 LENZ Therapeutics, Inc. - StreetInsider
Piper Sandler raises LENZ Therapeutics stock to Overweight - Investing.com Australia
Piper Sandler raises LENZ Therapeutics stock to Overweight By Investing.com - Investing.com Canada
Piper Sandler Projects Strong Growth for Lenz Therapeutics (LENZ) with LNZ100 | ABBV Stock News - GuruFocus
Lenz Therapeutics assumed with an Overweight at Piper Sandler - TipRanks
Wellington Management Group LLP Has $815,000 Stock Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Bought by Vanguard Group Inc. - Defense World
KLP Kapitalforvaltning AS Makes New $46,000 Investment in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of “Buy” by Brokerages - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Bought by American Century Companies Inc. - Defense World
8,485 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Bought by Raymond James Financial Inc. - Defense World
LENZ Therapeutics: Freedom From Reading Glasses (NASDAQ:LENZ) - Seeking Alpha
Presbyopia Treatment Market Size in 7MM is expected to grow at - openPR.com
18,900 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by Swiss National Bank - Defense World
Swiss National Bank Takes $546,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics Stock Is Attractive Before PDUFA (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Brokers Issue Forecasts for LENZ Q2 Earnings - Defense World
What is Leerink Partnrs’ Forecast for LENZ Q1 Earnings? - Defense World
William Blair Issues Negative Outlook for LENZ Earnings - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Price Target Raised to $47.00 - Defense World
Equities Analysts Offer Predictions for LENZ FY2026 Earnings - Defense World
What is HC Wainwright’s Estimate for LENZ Q1 Earnings? - Defense World
Lenz Therapeutics’ Earnings Call Highlights Positive Outlook - TipRanks
Promising Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid Strong Market Position and Upcoming Product Launch - TipRanks
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Defense World
Citi raises LENZ Therapeutics price target to $47, keeps Buy rating - Investing.com Australia
LENZ Therapeutics stock holds $38 target on FDA approval optimism By Investing.com - Investing.com Australia
LENZ Therapeutics stock holds $38 target on FDA approval optimism - Investing.com
Citi ups PT on LENZ Therapeutics on eye-drop approval confidence - TradingView
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lenz Therapeutics Inc-Aktie (LENZ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 07 '25 |
Option Exercise |
1.04 |
4,200 |
4,368 |
49,200 |
| Olsson Shawn | Chief Commercial Officer |
Dec 16 '24 |
Option Exercise |
2.08 |
3,333 |
6,933 |
3,333 |
| Schimmelpennink Evert B. | President, CEO and Secretary |
Jul 22 '24 |
Option Exercise |
1.04 |
45,000 |
46,800 |
45,000 |
| Chevallard Daniel R. | Chief Financial Officer |
May 14 '24 |
Buy |
15.68 |
3,188 |
49,988 |
3,188 |
| MCCOLLUM JAMES W | Director |
May 13 '24 |
Buy |
15.99 |
31,332 |
501,093 |
525,565 |
1.93%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):